Basic fibroblast growth factor and Shiga toxin-O157:H7-associated hemolytic uremic syndrome

Journal of the American Society of Nephrology

Volumn 13, Issue 3, 2002, Pages 817-820

  Tarr, Phillip I ^a  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; SHIGA TOXIN;

CLINICAL FEATURE; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DISEASE COURSE; EDITORIAL; ESCHERICHIA COLI O157; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOPATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; THROMBOCYTE COUNT;

EID: 0036188415     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (60)

1. Escherichia coli Shiga toxin
2. Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome
3. Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome
4. Inflammatory mediators in Escherichia coli O157:H7 hemorrhagic colitis and hemolytic-uremic syndrome
5. Circulating levels of transforming growth factor-beta 1 and lymphokines among children with hemolytic uremic syndrome
6. Von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O 157:H7-associated hemolytic uremic syndrome
7. Prothrombotic coagulation abnormalities preceding the hemolytic uremic syndrome
8. Responses of human intestinal microvascular endothelial cells to Shiga toxins 1 and 2 and pathogenesis of hemorrhagic colitis
9. Human microvascular endothelial cells are strongly sensitive to Shiga toxins
10. Sensitization of human umbilical vein endothelial cells to Shiga toxin: Involvement of protein kinase C and NF-kappaB
11. Effect of TNF-alpha, shiga toxin and calcium ionophore on Weibel-Palade body content of endothelial cells: Possible implications for the hemolytic uremic syndrome
12. Shiga toxin-associated hemolytic uremic syndrome: Effect of sodium butyrate on sensitivity of human umbilical vein endothelial cells to Shiga toxin
13. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro
14. Shiga toxin-associated hemolytic uremic syndrome: Interleukin- 1 beta enhancement of shiga toxin cytotoxicity toward human vascular endothelial cells in vitro
15. Endothelial heterogeneity in shiga toxin receptors and responses
16. Shiga toxin-associated hemolytic uremic syndrome: Combined cytotoxic effects of shiga toxin and lipopolysaccharide (endotoxin) on human vascular endothelial cells in vitro
17. Shiga toxin-associated hemolytic-uremic syndrome: Combined cytotoxic effects of Shiga toxin, interleukin- 1 beta, and tumor necrosis factor alpha on human vascular endothelial cells in vitro
18. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice
19. Direct cytotoxic action of Shiga toxin on human vascular endothelial cells
20. Pathogenic mechanism of mouse brain damage caused by oral infection with Shiga toxin-producing Escherichia coli O157:H7
21. Verocytotoxin-induced apoptosis of human microvascular endothelial cells
22. Shiga toxin-induced tumor necrosis factor alpha expression: Requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases
23. Anisodamine inhibits shiga toxin type 2-mediated tumor necrosis factor-alpha production in vitro and in vivo
24. Inhibition of Shiga toxin-induced tumor necrosis factor-alpha production and gene expression in human monocytic cells by CV 6209
25. Shiga toxin type 1 activates tumor necrosis factor-alpha gene transcription and nuclear translocation of the transcriptional activators nuclear factor-kappaB and activator protein-1
26. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines
27. Evidence for participation of the macrophage in Shiga-like toxin II-induced lethality in mice
28. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome
29. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections
30. Renal microangiopathy of the hemolytic-uremic syndrome in childhood
31. Pathology of the hemolytic uremic syndrome
32. Characterization of the baboon responses to Shiga-like toxin: Descriptive study of a new primate model of toxic responses to Stx-1
33. Endothelial cell dysfunction and coagulation
34. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome
35. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome
36. Platelet activation by Shiga toxin and circulatory factors as a pathogenetic mechanism in the hemolytic uremic syndrome
37. Activation of beta(2)-adrenoceptor prevents Shiga toxin 2-induced TNF-alpha gene transcription
38. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains
39. Cytotoxic effect of Shiga toxin- 1 on human proximal tubule cells
40. Shiga toxin induces medullary tubular injury in isolated perfused rat kidneys
41. The detection of Shiga toxins in the kidney of a patient with hemolytic uremic syndrome
42. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections
43. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections
44. Escherichia coli O157:H7
45. Escherichia coli O157:H7 and the hemolytic uremic syndrome: Importance of early cultures in establishing etiology
46. Lessons learned in the management of hemolytic uremic syndrome in children
47. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome
48. Localization of fibroblast growth factor-2 (basic FGF) and FGF receptor- 1 in adult human kidney
49. Potential autocrine and paracrine mechanisms of recovery from mechanical injury of renal tubular epithelial cells
50. Autocrine growth regulation of human glomerular mesangial cells is primarily mediated by basic fibroblast growth factor
51. Basic fibroblast growth factor in HIV-associated hemolytic uremic syndrome
52. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition
53. Vascular endothelial growth factor (VEGF121), protects rats from renal infarction in thrombotic microangiopathy
54. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy
55. Infusion of platelet-derived growth factor or basic fibroblast growth factor induces selective glomerular mesangial cell proliferation and matrix accumulation in rats
56. Regulation of rat proximal tubule epithelial cell growth by fibroblast growth factors, insulin-like growth factor- 1 and transforming growth factor-beta, and analysis of fibroblast growth factors in rat kidney
57. Endogenous fibroblast growth factor-2 mediates cytotoxicity in experimental mesangio-proliferative glomerulonephritis
58. Rat glomerular mesangial cells synthesize basic fibroblast growth factor. Release, upregulated synthesis, and mitogenicity in mesangial proliferative glomerulonephritis
59. Basic fibroblast growth factor augments podocyte injury and induces glomerulosclerosis in rats with experimental membranous nephropathy